AGP Executive Report
Last update: 3 hours agoGLP-1 Safety: The FDA is requiring vision-loss warnings on drugs including Ozempic and Wegovy. The risk appears rare, and eye specialists advise patients not to stop treatment without consulting a doctor; seek prompt care for sudden vision loss. More Targeted Care: New rheumatoid arthritis studies aim to improve how doctors measure joint inflammation and choose treatments. Separate late-stage trials found experimental weight-loss drug retatrutide reduced knee pain in people with obesity and osteoarthritis. Mental Health: An analysis of 115 studies suggests Lexapro and Cymbalta may provide longer-lasting relief from depression than Prozac, though treatment choices should be made with a clinician. Workplace Health: The American Medical Association backed a near-complete U.S. ban on high-silica engineered stone, linked to deadly silicosis among countertop workers. Infectious Disease: U.S. measles cases have topped 5,000, putting the country at risk of losing its measles-elimination status as health experts review the outbreak.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
